Tuesday, April 16, 2024

FDA Approves Allergan’s Temple Hollowing Treatment Juvéderm, a First in HA Dermal Fillers

Similar articles

Allergan Aesthetics, a subsidiary of AbbVie, has received FDA approval for Juvéderm Voluma XC to address moderate to severe temple hollowing in adults aged 21 and above. This announcement marks a significant advancement in aesthetic treatments, as Juvéderm Voluma becomes the first hyaluronic acid (HA) dermal filler approved by the FDA for temple hollowing.

Carrie Strom, the esteemed President of Allergan Aesthetics and Senior Vice President of AbbVie, articulated the profound commitment of the company to pioneering innovation and fulfilling patient needs through the recent FDA approval. With this milestone achievement, Strom underscored the pivotal significance of addressing temple hollowing, an aspect of facial aging that has historically received inadequate attention within the realm of aesthetic treatments. She emphasized that Allergan Aesthetics has strategically prioritized the development of solutions that specifically target temple hollowing, recognizing it as a critical area where patients seek enhancement and restoration.

Strom’s remarks reflect the culmination of extensive research, innovative product development, and a deep understanding of patient concerns within the aesthetic industry. By acknowledging the underrepresentation of temple hollowing treatments, Allergan Aesthetics demonstrates its unwavering commitment to advancing the field of aesthetic medicine and elevating standards of care for patients seeking comprehensive facial rejuvenation.

Moreover, Strom’s emphasis on addressing temple hollowing underscores the company’s proactive approach to identifying and addressing unmet patient needs. By recognizing and responding to evolving patient preferences and concerns, Allergan Aesthetics reaffirms its position as a leader in aesthetic innovation and patient-centric care. Strom’s leadership highlights the company’s dedication to pushing the boundaries of aesthetic medicine, ensuring that patients have access to cutting-edge treatments that deliver transformative results and enhance their quality of life.

Allergan Aesthetics Enhances Beauty Standards with Juvéderm Voluma XC, Promising Facial Rejuvenation and Training for Providers

In essence, Strom’s remarks encapsulate Allergan Aesthetics’ unwavering commitment to innovation, patient care, and addressing the evolving needs of individuals seeking aesthetic enhancements. Through strategic focus and relentless dedication to excellence, the company continues to redefine standards within the aesthetic industry, empowering patients to embrace their beauty and confidence with newfound vitality and authenticity.

Clinical studies have shown promising results with Juvéderm Voluma XC, with approximately 80% of participants reporting satisfaction with the treatment outcomes lasting up to 13 months post-treatment. The medication not only addresses temple hollowing but also contributes to facial rejuvenation and a rested appearance, as evidenced by positive feedback from study participants.

Furthermore, Allergan plans to launch a comprehensive training program to ensure the safe and effective use of Juvéderm Voluma XC by healthcare providers. This initiative underscores the company’s commitment to patient safety and optimal treatment outcomes.

Temple Hollowing

Juvéderm Voluma XC’s FDA Approval for Temple Hollowing Marks a Milestone in Aesthetic Medicine

Dr. Deirdre Hooper, a board-certified dermatologist and clinical trial investigator, emphasized the significance of incorporating Juvéderm Voluma XC into a holistic approach to facial enhancement. She highlighted the potential of the treatment to provide subtle yet impactful improvements, contributing to a more youthful and balanced facial appearance.

This approval builds upon the FDA’s previous endorsement of Juvéderm Voluma XC for undereye hollows, further solidifying Allergan Aesthetics’ position as a leader in aesthetic innovation. The positive feedback from participants in associated clinical trials underscores the effectiveness and patient satisfaction associated with Juvéderm Voluma XC.

Carrie Strom reiterated the company’s commitment to innovation and addressing patient concerns, particularly in areas such as undereye hollows and temple hollowing. She emphasized the comprehensive portfolio of treatment options offered by Allergan Aesthetics, ranging from skincare solutions to advanced injectable treatments.

In summary, the FDA approval of Juvéderm Voluma XC for moderate to severe temple hollowing represents a significant milestone in aesthetic medicine. This endorsement reflects Allergan Aesthetics’ dedication to innovation and patient-centered care, providing healthcare providers and patients with safe and effective treatment options for facial rejuvenation and enhancement.

 

Resource: Pharmexec, March 05, 2024

Subscribe to our newsletter

To be updated with all the latest news, offers and special announcements.

Latest article